| 1 |
Hameed AM,Hawthorne WJ,Pleass HC. Advances in organ preservation for transplantation[J]. ANZ J Surg, 2016.
|
| 2 |
Shivaswamy V,Boerner B,Larsen J. Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes[J]. Endocr Rev, 2016, 37(1): 37-61.
|
| 3 |
Han E,Kim MS,Kim YS, et al. Risk assessment and management of post-transplant diabetes mellitus[J]. Metabolism, 2016, 65(10): 1559-1569.
|
| 4 |
Sharif A. Treatment options for post-transplantation diabetes mellitus[J]. Curr Diabetes Rev, 2015, 11(3): 155-162.
|
| 5 |
Haidinger M,Antlanger M,Kopecky C, et al. Post-transplantation diabetes mellitus: evaluation of treatment strategies[J]. Clin Transplant, 2015, 29(5): 415-424.
|
| 6 |
Liu J,Farmer JJ,Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes[J]. Cell, 1991, 66(4): 807-815.
|
| 7 |
Abou-Jaoude MM,Najm R,Shaheen J, et al. Tacrolimus (FK506) versus cyclosporine microemulsion (neoral) as maintenance immunosuppression therapy in kidney transplant recipients[J]. Transplant Proc, 2005, 37(7): 3025-3028.
|
| 8 |
Morris-Stiff G,Ostrowski K,Balaji V, et al. Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases[J]. Transpl Int, 1998, 11(Suppl 1): S334-S336.
|
| 9 |
Vincenti F,Friman S,Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus[J]. Am J Transplant, 2007, 7(6): 1506-1514.
|
| 10 |
Kasiske BL,Snyder JJ,Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States[J]. Am J Transplant, 2003, 3(2): 178-185.
|
| 11 |
Ghisdal L,Van Laecke S,Abramowicz MJ, et al. New-onset diabetes after renal transplantation: risk assessment and management[J]. Diabetes Care, 2012, 35(1): 181-188.
|
| 12 |
Collins AJ,Foley RN,Chavers B, et al. United States Renal Data System 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States[J]. Am J Kidney Dis, 2012, 59(1 Suppl 1): A7, e1-e420.
|
| 13 |
Lee S,Moon JY,Lee SH, et al.Angiotensinogen polymorphisms and post-transplantation diabetes mellitus in Korean renal transplant subjects[J]. Kidney Blood Press Res, 2013, 37(2-3): 95-102.
|
| 14 |
Weng LC,Chiang YJ,Lin MH, et al. Association between use of FK506 and prevalence of post-transplantation diabetes mellitus in kidney transplant patients[J]. Transplant Proc, 2014, 46(2): 529-531.
|
| 15 |
Filler G,Webb NJ,Milford DV, et al. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs cyclosporin microemulsion[J]. Pediatr Transplant, 2005, 9(4): 498-503.
|
| 16 |
Yao B,Chen X,Shen FX, et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism[J]. Transplant Proc, 2013, 45(1): 194-196.
|
| 17 |
Heisel O,Heisel R,Balshaw R, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis[J]. Am J Transplant, 2004, 4(4): 583-595.
|
| 18 |
Prokai A,Fekete A,Pasti K, et al. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus[J]. Pediatr Diabetes, 2012, 13(1): 81-91.
|
| 19 |
Burroughs TE,Swindle JP,Salvalaggio PR, et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients[J]. Transplantation, 2009, 88(3): 367-373.
|
| 20 |
Al-Uzri A,Stablein DM,A Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)[J]. Transplantation, 2001, 72(6): 1020-1024.
|
| 21 |
Hathout E,Alonso E,Anand R, et al. Post-transplant diabetes mellitus in pediatric liver transplantation[J]. Pediatr Transplant, 2009, 13(5): 599-605.
|
| 22 |
Hathout EH,Chinnock RE,Johnston JK, et al. Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients[J]. Am J Transplant, 2003, 3(8): 994-998.
|
| 23 |
Prokai A,Fekete A,Kis E, et al. Post-transplant diabetes mellitus in children following renal transplantation[J]. Pediatr Transplant, 2008, 12(6): 643-649.
|
| 24 |
Kuo HT,Poommipanit N,Sampaio M, et al. Risk factors for development of new-onset diabetes mellitus in pediatric renal transplant recipients: an analysis of the OPTN/UNOS database[J]. Transplantation, 2010, 89(4): 434-439.
|
| 25 |
Garro R,Warshaw B,Felner E. New-onset diabetes after kidney transplant in children[J]. Pediatr Nephrol, 2015, 30(3): 405-416.
|
| 26 |
Redmon JB,Olson LK,Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells[J]. J Clin Invest, 1996, 98(12): 2786-2793.
|
| 27 |
van Hooff JP,Christiaans MH,van Duijnhoven EM. Evaluating mechanisms of post-transplant diabetes mellitus[J]. Nephrol Dial Transplant, 2004, 19(6 Suppl): S8-S12.
|
| 28 |
Boots JM,van Duijnhoven EM,Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction[J]. J Am Soc Nephrol, 2002, 13(1): 221-227.
|
| 29 |
Rodrigo E,Pinera C,de Cos MA, et al. Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation[J]. Transpl Int, 2005, 18(10): 1152-1157.
|
| 30 |
Webster A,Woodroffe RC,Taylor RS, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients[J]. Cochrane Database Syst Rev, 2005, 4: CD003961.
|
| 31 |
Tamura K,Fujimura T,Tsutsumi T, et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell[J]. Transplantation, 1995, 59(11): 1606-1613.
|
| 32 |
Drachenberg CB,Klassen DK,Weir MR, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation[J]. Transplantation, 1999, 68(3): 396-402.
|
| 33 |
Shivaswamy V,Bennett RG,Clure CC, et al. Tacrolimus and sirolimus have distinct effects on insulin signaling in male and female rats[J]. Transl Res, 2014, 163(3): 221-231.
|
| 34 |
Johnson JD,Ao Z,Ao P, et al. Different effects of FK506, rapamycin, and mycophenolate mofetil on glucose-stimulated insulin release and apoptosis in human islets[J]. Cell Transplant, 2009, 18(8): 833-845.
|
| 35 |
Heit JJ,Apelqvist AA,Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function[J]. Nature, 2006, 443(7109): 345-349.
|
| 36 |
Soleimanpour SA,Crutchlow MF,Ferrari AM, et al. Calcineurin signaling regulates human islet {beta}-cell survival[J]. J Biol Chem, 2010, 285(51): 40050-40059.
|
| 37 |
Speckmann T,Sabatini PV,Nian C, et al. Npas4 Transcription factor expression is regulated by calcium signaling pathways and prevents tacrolimus-induced cytotoxicity in pancreatic beta cells[J]. J Biol Chem, 2016, 291(6): 2682-2695.
|
| 38 |
Rostambeigi N,Lanza IR,Dzeja PP, et al. Unique cellular and mitochondrial defects mediate FK506-induced islet beta-cell dysfunction[J]. Transplantation, 2011, 91(6): 615-623.
|
| 39 |
Romanowski M,Dziedziejko V,Maciejewska-Karlowska A, et al. Adiponectin and leptin gene polymorphisms in patients with post-transplant diabetes mellitus[J]. Pharmacogenomics, 2015, 16(11): 1243-1251.
|
| 40 |
Filippatos TD,Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function[J]. World J Diabetes, 2013, 4(5): 190-201.
|
| 41 |
Sanyal D,Gupta S,Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting[J]. Indian J Endocrinol Metab, 2013, 17(Suppl 1): S203-S205.
|
| 42 |
Soliman AR,Fathy A,Khashab S, et al. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant[J]. Exp Clin Transplant, 2013, 11(6): 494-498.
|
| 43 |
Lane JT,Odegaard DE,Haire CE, et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation[J]. Transplantation, 2011, 92(10): e56-e57.
|
| 44 |
Haidinger M,Werzowa J,Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial[J]. Am J Transplant, 2014, 14(1): 115-123.
|
| 45 |
Werzowa J,Hecking M,Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial[J]. Transplantation, 2013, 95(3): 456-462.
|
| 46 |
Hecking M,Werzowa J,Haidinger M, et al. Novel views on new-onset diabetes after transplantation：development, prevention and treatment[J]. Nephrol Dial Transplant, 2013, 28(3): 550-566.
|
| 47 |
Davidson J,Wilkinson A,Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines[J]. Transplantation, 2003, 75(10 Suppl): S3-S24.
|
| 48 |
Kurian B,Joshi R,Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients[J]. Endocr Pract, 2008, 14(8): 979-984.
|
| 49 |
Wissing KM,Pipeleers L. Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: prevention and treatment[J]. Transplant Rev (Orlando), 2014, 28(2): 37-46.
|
| 50 |
Luther P,Baldwin DJ. Pioglitazone in the management of diabetes mellitus after transplantation[J]. Am J Transplant, 2004, 4(12): 2135-2138.
|
| 51 |
Pietruck F,Kribben A,Van TN, et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation[J]. Transpl Int, 2005, 18(4): 483-486.
|
| 52 |
Villanueva G,Baldwin D. Rosiglitazone therapy of posttransplant diabetes mellitus[J]. Transplantation, 2005, 80(10): 1402-1405.
|
| 53 |
Juan KM,Ping CC. Prevention and management of new-onset diabetes mellitus in kidney transplantation[J]. Neth J Med, 2014, 72(3): 127-134.
|
| 54 |
Hecking M,Haidinger M,Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation[J]. J Am Soc Nephrol, 2012, 23(4): 739-749.
|